Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
1211
mi
from 91732
Austin, TX
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
1211
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
2468
mi
from 91732
Bennington, VT
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
2468
mi
from 91732
Bennington, VT
Click here to add this to my saved trials
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
6113
mi
from 91732
Ciudad Autonoma de Buenos Aires,
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
6113
mi
from 91732
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated:  11/7/2017
University Hospitals at Case Medical Center
2033
mi
from 91732
Cleveland, OH
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated: 11/7/2017
University Hospitals at Case Medical Center
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated:  11/7/2017
MetroHealth Med Ctr
2032
mi
from 91732
Cleveland, OH
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated: 11/7/2017
MetroHealth Med Ctr
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.
Status: Enrolling
Updated:  11/13/2017
Clinical Research Facility
13
mi
from 91732
Glendale, CA
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.
Status: Enrolling
Updated: 11/13/2017
Clinical Research Facility
13
mi
from 91732
Glendale, CA
Click here to add this to my saved trials
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  11/21/2017
Ageless Regenerative Institute LLC
2320
mi
from 91732
Aventura, FL
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 11/21/2017
Ageless Regenerative Institute LLC
2320
mi
from 91732
Aventura, FL
Click here to add this to my saved trials
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
CNS and Plasma Amyloid-Beta Kinetics in Alzheimers's Disease; A Blood Isotope Labeled Amyloid-beta Test for Alzheimer's Disease.
Status: Enrolling
Updated:  12/1/2017
Washington University in St. Louis
1568
mi
from 91732
Saint Louis, MO
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
CNS and Plasma Amyloid-Beta Kinetics in Alzheimers's Disease; A Blood Isotope Labeled Amyloid-beta Test for Alzheimer's Disease.
Status: Enrolling
Updated: 12/1/2017
Washington University in St. Louis
1568
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated:  12/6/2017
American College of Radiology Imaging Network
2374
mi
from 91732
Philadelphia, PA
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated: 12/6/2017
American College of Radiology Imaging Network
2374
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated:  12/6/2017
Https://Www.Ideas-Study.Org/Site-Locator/
2373
mi
from 91732
Philadelphia, PA
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated: 12/6/2017
Https://Www.Ideas-Study.Org/Site-Locator/
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of Alzheimer's Disease (AD)
Status: Enrolling
Updated:  12/8/2017
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of Alzheimer's Disease (AD)
Status: Enrolling
Updated: 12/8/2017
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
n-3 PUFA for Vascular Cognitive Aging
Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline
Status: Enrolling
Updated:  12/18/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
n-3 PUFA for Vascular Cognitive Aging
Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline
Status: Enrolling
Updated: 12/18/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Altman Clinical and Translational Research Institute
94
mi
from 91732
La Jolla, CA
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Altman Clinical and Translational Research Institute
94
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Memory Enhancement Center of America, Inc.
2431
mi
from 91732
Eatontown, NJ
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Memory Enhancement Center of America, Inc.
2431
mi
from 91732
Eatontown, NJ
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Community Clinical Research
1215
mi
from 91732
Austin, TX
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Community Clinical Research
1215
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Collaborative Neuroscience Network - CNS
21
mi
from 91732
Long Beach, CA
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Collaborative Neuroscience Network - CNS
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Compass Research LLC
2184
mi
from 91732
Orlando, FL
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Compass Research LLC
2184
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Atlanta Center for Medical Research
1919
mi
from 91732
Atlanta, GA
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Atlanta Center for Medical Research
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Prahealthsciences
569
mi
from 91732
Salt Lake City, UT
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Prahealthsciences
569
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from 91732
Sumida-Ku,
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from 91732
Sumida-Ku,
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US101
346
mi
from 91732
Phoenix, AZ
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US101
346
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US102
1931
mi
from 91732
Ann Arbor, MI
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US102
1931
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US108
1810
mi
from 91732
Pensacola, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US108
1810
mi
from 91732
Pensacola, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US106
1902
mi
from 91732
Columbus, GA
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US106
1902
mi
from 91732
Columbus, GA
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US107
1792
mi
from 91732
Indianapolis, IN
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US107
1792
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US118
46
mi
from 91732
Simi Valley, CA
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US118
46
mi
from 91732
Simi Valley, CA
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US117
64
mi
from 91732
Temecula, CA
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US117
64
mi
from 91732
Temecula, CA
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US115
2312
mi
from 91732
Boca Raton, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US115
2312
mi
from 91732
Boca Raton, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US109
2318
mi
from 91732
Hallandale Beach, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US109
2318
mi
from 91732
Hallandale Beach, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US116
2322
mi
from 91732
Miami, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US116
2322
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US111
1960
mi
from 91732
Columbus, OH
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US111
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated:  12/27/2017
Columbia University Medical Center
2432
mi
from 91732
New York, NY
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated: 12/27/2017
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Status: Enrolling
Updated:  1/3/2018
VA Palo Alto Health Care System
327
mi
from 91732
Palo Alto, CA
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Status: Enrolling
Updated: 1/3/2018
VA Palo Alto Health Care System
327
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Status: Enrolling
Updated:  1/3/2018
Research Imaging Institute, The University of Texas Health Science Center at San Antonio
1182
mi
from 91732
San Antonio, TX
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Status: Enrolling
Updated: 1/3/2018
Research Imaging Institute, The University of Texas Health Science Center at San Antonio
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated:  1/4/2018
Johns Hopkins Bayview
2301
mi
from 91732
Baltimore, MD
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated: 1/4/2018
Johns Hopkins Bayview
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated:  1/4/2018
Reading Hospital
2332
mi
from 91732
West Reading, PA
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated: 1/4/2018
Reading Hospital
2332
mi
from 91732
West Reading, PA
Click here to add this to my saved trials
Trial of Carvedilol in Alzheimer's Disease
Pilot Trial of Carvedilol in Alzheimer's Disease
Status: Enrolling
Updated:  1/8/2018
Johns Hopkins School of Medicine Bayview Campus
2301
mi
from 91732
Baltimore, MD
Trial of Carvedilol in Alzheimer's Disease
Pilot Trial of Carvedilol in Alzheimer's Disease
Status: Enrolling
Updated: 1/8/2018
Johns Hopkins School of Medicine Bayview Campus
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
330
mi
from 91732
Sun City, AZ
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
330
mi
from 91732
Sun City, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
207
mi
from 91732
Fresno, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
207
mi
from 91732
Fresno, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
13
mi
from 91732
Fullerton, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
13
mi
from 91732
Fullerton, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
105
mi
from 91732
San Diego, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
355
mi
from 91732
San Francisco, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
26
mi
from 91732
Sherman Oaks, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
26
mi
from 91732
Sherman Oaks, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
62
mi
from 91732
Temecula, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
62
mi
from 91732
Temecula, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
2309
mi
from 91732
Boynton Beach, FL
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
2309
mi
from 91732
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
2312
mi
from 91732
Deerfield Beach, FL
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
2312
mi
from 91732
Deerfield Beach, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Click here to add this to my saved trials